Walter Bushnell Medicines Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 17 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 12.28%
(FY 2022)
- Profit -1.28%
(FY 2022)
- Ebitda -11.96%
(FY 2022)
- Net Worth 17.52%
(FY 2022)
- Total Assets 53.76%
(FY 2022)
About Walter Bushnell Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Surendra Jangir, Bharat Sharma, and Brij Nandan serve as directors at the Company.
- CIN/LLPIN
U24232HR2007PTC071119
- Company No.
071119
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Walter Bushnell Medicines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendra Jangir  | Director | 27-Jun-2007 | Current |
| Bharat Sharma | Director | 06-Feb-2015 | Current |
| Brij Nandan | Director | 09-Mar-2015 | Current |
Financial Performance and Corporate Structure Insights of Walter Bushnell Medicines.
Walter Bushnell Medicines Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 12.28% increase. The company also saw a slight decrease in profitability, with a 1.28% decrease in profit. The company's net worth Soared by an impressive increase of 17.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Walter Bushnell Medicines?
In 2020, Walter Bushnell Medicines had a promoter holding of 59.71% and a public holding of 40.29%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Walter Bushnell Pharmaceuticals Private LimitedActive 20 years 10 daysSurendra Jangir is a mutual person
Walter Bushnell Healthsciences Private LimitedActive 17 years 5 monthsBrij Nandan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Walter Bushnell Medicines?
Walter Bushnell Medicines has a workforce of 204 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Walter Bushnell Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Walter Bushnell Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
